United States · FDA National Drug Code directory
MONJUVI
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50881-013_a70f85e0-c22b-419a-9be2-51f575932633
- Product NDC
- 50881-013
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- Tafasitamab-cxix
- Labeler
- Incyte Corporation
- Marketing category
- BLA
- Marketing start / end (source format)
- 20200805
- Source listing expiry
- 20261231
Source-listed ingredients
- TAFASITAMAB — 200 mg/5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL in 1 CARTON (50881-013-03) / 5 mL in 1 VIAL · 50881-013-03
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →